New study checks how liver issues affect cancer drug pelabresib
NCT ID NCT07422610
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This research aims to find the right dose for patients with liver impairment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pelabresib
What this could lead to
If successful, this study could help doctors determine the right dose of pelabresib for patients with liver problems, potentially making treatment safer and more effective.
What could go wrong
This is a very early, small study (24 people) focused on drug levels, not on curing cancer. It may not lead to any new treatments, and liver impairment could increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGBordeaux, 33075, France
-
Novartis Investigative Site
RECRUITINGCandiolo, TO, 10060, Italy
-
Novartis Investigative Site
RECRUITINGPozuelo de Alarcón, Madrid, 28223, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08023, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28040, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28050, Spain
-
Novartis Investigative Site
RECRUITINGLondon, W12 0HS, United Kingdom